The primary goal of this Mucosal Biology Scientific Research Support Component (SRSC) is to identify antibody effector functions at mucosal surfaces required to prevent HIV-1 acquisition, define how they differ by route of transmission, and through integrated studies across SRSCs (Mucosal, Vector, Non-human Primate) determine modes of protective antibody induction in non-human primates and in collaborative human clinical vaccine studies.
Specific Aims Aim 1. To support CHAVI-ID by defining the functional nature of protective antibody responses at mucosal surfaces elicited in RV144 follow-on trials (RV306, RV328), in other HlV-1 vaccine trials (HVTN 204, 082, 076) and in the HVTN/CHAVI501 mosaic trial.
Aim 2. To support CHAVI-ID by assessing the functional characteristics of protective antibodies at mucosal surfaces in NHP Core studies designed to determine optimal route/adjuvant combinations for the induction of mucosal immunity.
Aim 3. To support CHAVI-ID by evaluating the functional characteristics of protective antibodies at mucosal surfaces in NHP and Vector SRSC studies designed to determine optimal vector strategies for the induction of mucosal immunity.
Aim 4. To support CHAVI-ID by determining the impact of dimeric vs monomeric antibodies on mucosal acquisition.

Public Health Relevance

The primary goal of this project is to identify the most effective components of vaccine induced responses at mucosal surfaces (vagina, rectum and penis) required to prevent HIV infection and to develop vaccine strategies that will induce and maintain such responses for a prolonged period (years).

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Chen, Shuobing; Wu, Jiayi; Lu, Ying et al. (2016) Structural basis for dynamic regulation of the human 26S proteasome. Proc Natl Acad Sci U S A 113:12991-12996
Tian, Ming; Cheng, Cheng; Chen, Xuejun et al. (2016) Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166:1471-1484.e18
Love, Tanzy M T; Park, Sung Yong; Giorgi, Elena E et al. (2016) SPMM: estimating infection duration of multivariant HIV-1 infections. Bioinformatics 32:1308-15
Barton, John P; Goonetilleke, Nilu; Butler, Thomas C et al. (2016) Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nat Commun 7:11660
Astronomo, Rena D; Santra, Sampa; Ballweber-Fleming, Lamar et al. (2016) Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine 14:97-111
Herschhorn, Alon; Ma, Xiaochu; Gu, Christopher et al. (2016) Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. MBio 7:
Theiler, James; Yoon, Hyejin; Yusim, Karina et al. (2016) Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci Rep 6:33987
Ding, Shilei; Tolbert, William D; Prévost, Jérémie et al. (2016) A Highly Conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability. J Virol 90:8395-409
Jeffries Jr, T L; Sacha, C R; Pollara, J et al. (2016) The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. Mucosal Immunol 9:414-27
Abdul-Jawad, Sultan; Ondondo, Beatrice; van Hateren, Andy et al. (2016) Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Mol Ther 24:375-84

Showing the most recent 10 out of 160 publications